Literature DB >> 1932305

Medullary histiocytosis following treatment of severe aplastic anemia with recombinant human interleukin-3 in combination with antilymphocyte globulin, cyclosporin A, and methylprednisolone.

F Herrmann1, A Lindemann, W Lange, G Köchling, A Raghavachar, H Schrezenmeier, N Frickhofen, R H Mertelsmann.   

Abstract

This case report describes the clinical use of recombinant human interleukin-3 as adjunct to immunosuppressive therapy with antilymphocyte globulin, cyclosporin A, and methylprednisolone for refractory severe aplastic anemia. Hematopoietic response to treatment was moderate and peripheral blood counts (neutrophils, eosinophils, monocytes, reticulocytes) increased only slightly. Unexpectedly, during the time of interleukin-3 administration a substantial bone marrow infiltration by macrophages became detectable, consistent with the diagnosis of medullary histiocytosis, that may have prevented recovery of normal hematopoiesis in this patient. This observation may indicate the need for careful use of interleukin-3 in patients with drug-induced immunodeficiency.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1932305     DOI: 10.1007/bf01703450

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  11 in total

1.  A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia.

Authors:  B M Camitta; E D Thomas; D G Nathan; R P Gale; K J Kopecky; J M Rappeport; G Santos; E C Gordon-Smith; R Storb
Journal:  Blood       Date:  1979-03       Impact factor: 22.113

2.  Current status of bone marrow transplantation for severe aplastic anemia: a preliminary report from the International Bone Marrow Transplant Registry.

Authors:  E Gluckman
Journal:  Transplant Proc       Date:  1987-02       Impact factor: 1.066

3.  Antithymocyte globulin treatment in patients with aplastic anemia: a prospective randomized trial.

Authors:  R Champlin; W Ho; R P Gale
Journal:  N Engl J Med       Date:  1983-01-20       Impact factor: 91.245

4.  Therapy of severe aplastic anemia in young adults and children with allogeneic bone marrow transplantation.

Authors:  P B McGlave; R Haake; W Miller; T Kim; J Kersey; N K Ramsay
Journal:  Blood       Date:  1987-11       Impact factor: 22.113

5.  In vivo recruitment of GM-CSF-response myelopoietic progenitor cells by interleukin-3 in aplastic anemia.

Authors:  F Herrmann; A Lindemann; A Raghavachar; H Heimpel; R Mertelsmann
Journal:  Leukemia       Date:  1990-10       Impact factor: 11.528

6.  Human recombinant granulocyte-macrophage colony stimulating factor and interleukin 3 have overlapping but distinct hematopoietic activities.

Authors:  S G Emerson; Y C Yang; S C Clark; M W Long
Journal:  J Clin Invest       Date:  1988-10       Impact factor: 14.808

7.  Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group.

Authors:  N Frickhofen; J P Kaltwasser; H Schrezenmeier; A Raghavachar; H G Vogt; F Herrmann; M Freund; P Meusers; A Salama; H Heimpel
Journal:  N Engl J Med       Date:  1991-05-09       Impact factor: 91.245

8.  Effects of recombinant human interleukin-3 in aplastic anemia.

Authors:  A Ganser; A Lindemann; G Seipelt; O G Ottmann; M Eder; S Falk; F Herrmann; J P Kaltwasser; P Meusers; M Klausmann
Journal:  Blood       Date:  1990-10-01       Impact factor: 22.113

9.  Virus-associated hemophagocytic syndrome: a benign histiocytic proliferation distinct from malignant histiocytosis.

Authors:  R J Risdall; R W McKenna; M E Nesbit; W Krivit; H H Balfour; R L Simmons; R D Brunning
Journal:  Cancer       Date:  1979-09       Impact factor: 6.860

10.  Human granulocyte-monocyte colony-stimulating factor and interleukin 3 stimulate monocyte cytotoxicity through a tumor necrosis factor-dependent mechanism.

Authors:  S A Cannistra; E Vellenga; P Groshek; A Rambaldi; J D Griffin
Journal:  Blood       Date:  1988-03       Impact factor: 22.113

View more
  3 in total

Review 1.  Clinical toxicity of cytokines used as haemopoietic growth factors.

Authors:  T Vial; J Descotes
Journal:  Drug Saf       Date:  1995-12       Impact factor: 5.606

2.  Cytokine serum levels during treatment with high-dose recombinant human IL-3 in a patient with severe aplastic anemia.

Authors:  D Nachbaur; A Gratwohl; M Herold; A Tichelli; M Slanicka; C Nissen; D Niederwieser; B Speck
Journal:  Ann Hematol       Date:  1993-02       Impact factor: 3.673

3.  Fatal hematophagic histiocytosis after granulocyte-macrophage colony-stimulating factor and chemotherapy for high-grade malignant lymphoma.

Authors:  B Risti; R F Flury; A Schaffner
Journal:  Clin Investig       Date:  1994-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.